Abstract:Background: Immune-mediated necrotizing myopathy (IMNM) is characterized by proximal muscle weakness, elvated serum muscle enzyme levels, myopathic electromyography findings, and necrotic muscle fiber with few inflammatory cell infiltration in muscle biopsies. Statins, the first line drug to lower triglyceride and cholesterol level in blood, have been reported to be associated with statins-induced necrotizing autoimmune myopathy (SINAM). Although anti-3-hydroxy-3-methylglutarylcoenzyme-A reductase (anti-HMGCR) myopathy is considered as the leading myopathy related to the statins medication, anti-signal recognition particle (SRP) myopathy were also identified in several cases with statin exposure. The risk of deep venous thrombosis (DVT) is substantially high in individuals with autoimmune inflammatory diseases. But few studies have reported the occurrence and recommendation for treatment of DVT in patients with anti-SRP myopathy. Here, we reported a statin-exposed anti-SRP myopathy individual developed DVT who was successfully treated with catheter-directed thrombolysis (CDT) and systemic anticoagulants therapy. Case presentation: A 56-year-old Chinese female came to the outpatient room with gradually progressive bilateral lower-extremity weakness. Magnetic resonance imaging revealed myopathy in bilateral thighs. Serum anti-SRP antibody was positive. She was diagnosed with anti-SRP myopathy. When treated with corticosteroids and immunosuppressants, the patient developed mild edema and pain of left lower extremity. Angiography and ultrasound revealed diffuse venous thrombosis of left lower extremity. Therapy was initiated with CDT and lower molecular weight heparin, then switched to once daily oral rivaroxaban. Meanwhile, steroids combined with tacrolimus were also carried on while simvastatin was discontinued. One month later, patient's symptoms were resolved and only partial thrombosis in left femoral vein was remained. Conclusion: The prevalence of DVT in patient with anti-SRP myopathy was rare. No well-established treatment strategy is available to manage the IMNM and DVT at the same time. The systemic anticoagulants therapy combined CDT can be an effective therapeutic approach to address extensive DVT in patient with anti-SRP myopathy.

Unveiling the Enigma of Statin-Induced Necrotizing Autoimmune Myopathy: A Comprehensive Case Analysis and Pathogenic Insights

Statin-associated muscle symptoms: A comprehensive exploration of epidemiology, pathophysiology, diagnosis, and clinical management strategies

Immune-Mediated Necrotizing Myopathy Manifesting after Five Years of Statin Therapy

A Case of Statin-Associated Autoimmune Myopathy: Management and Treatment

Refractory Statin-Induced Immune-Mediated Necrotizing Myositis: Challenges and Perils in Its Management

A Neuropathy Mimic: Statin-Induced Myopathy Presenting as Guillain-Barré Syndrome

Statin-Induced Autoimmune Myopathy: A Diagnostic Challenge in Muscle Weakness

Incidence of statin-associated muscle symptoms in patients taking statins with RYR1 or CACNA1S variants

Statin-induced immune-mediated necrotizing myopathy with concomitant increase of anti-HMGCR and anti-ACHR antibodies

Statin-induced debilitating weakness and myopathy

Statins and immune-mediated necrotizing myopathy: Variability in the risk

Narrative Review: Statin-Related Myopathy

Rosuvastatin-Induced Myopathy: A Case Series

Deep venous thrombosis in an individual with statin-exposed anti-SRP myopathy: case report and review of literature

The first reported familial case of statin-induced immune-mediated necrotizing myopathy associated with anti-hydroxy-3-methylglutaryl-CoA reductase autoantibodies and HLA DRB1*11:01

[Statin-associated muscle symptoms : performance and quality of life]

An atorvastatin‐induced positive anti‐HMGCR immune‐mediated necrotizing myopathy case

Potential Benefits and Risks Associated with the Use of Statins

[The Clinical and Muscular Pathological Features of Statin-Induced Myopathy].

Development and Validation of the Pharmacological Statin‐Associated Muscle Symptoms Risk Stratification Score Using Electronic Health Record Data

Development and validation of the pharmacological statin-associated muscle symptoms risk stratification (PSAMS-RS) score using real-world electronic health record data